ангиотензин-II 和血栓栓塞发事件:一个系统性审查
Rebecca Caragata1,2, Samuel A Johnston1, Jian Wen Chan1,3
1Department of Anaesthesia, Austin Health, Melbourne, VIC, Australia.
Critical care medicine
|December 5, 2024
概括
已发表的证据并未证实或否认血管酶二和血栓栓塞事件之间的联系. 需要更多的研究和明确的标准来评估血管素II在患者中的安全性.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 关键护理医学 关键护理医学
背景情况:
- ангиотензин-II 用于治疗休克.
- 血栓栓塞栓事件是血管活性药物的潜在问题.
研究的目的:
- 系统地审查和综合有关 ангиотензин-II 与血栓栓塞事件 (VTE 和动脉) 相关的证据.
主要方法:
- 随机试验和比较观察性研究的系统审查.
- 在PubMed,Scopus和CENTRAL数据库中进行了搜索.
- 包括7项研究 (1461名患者);评估偏差风险.
主要成果:
- 在包含的研究中存在偏差的高风险,排除了定量合成.
- 血管血栓事件的发生率在血管素II和对照组之间是相似的 (VTE:8.8%与9.4%;动脉:11.3%与12.7%).
结论:
- 目前的证据不足以支持或驳斥 ангиотензин-II与增加的血栓栓塞风险之间的关联.
- 未来的研究需要对血栓塞栓事件进行标准化的诊断和报告标准.
相关概念视频
Antihypertensive Drugs: Angiotensin II Receptor Blockers
581
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
581
Antihypertensive Drugs: Direct Renin Inhibitors
490
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
490
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
385
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
385
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
477
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
477
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
135
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
135
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
468
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
468


